Skip to content
Screener

Operating Cash Flow at other companies

Merck & Co. logo
Merck & Co.MRK
$5.37B+63.1%
Savara logo
SavaraSVRA
-$33.05M-21.5%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
-$9M-112%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$73.28M+70.3%
LQD
Liquidia CorporationLQDA
$52.99M+273%
United Therapeutics logo
United TherapeuticsUTHR
$313.6M+63.6%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.63B+197%
Enterprise value$2.61B+239%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206390
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Accrued expenses and other liabilities(1,075)(1,501)
Accounts payable(1,483)(1,993)
Prepaid expenses and other current assets(2,838)(605)
Net cash used in operating activities(16,689)(13,477)
Investing activities:
Proceeds from maturities of available-for-sale marketable securities25,55217,595
Purchases of available-for-sale marketable securities(8,485)(27,546)
Purchases of property, equipment and leasehold improvements(102)

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is Trevi Therapeutics, Inc.'s operating cash flow?
Trevi Therapeutics, Inc. (TRVI) reported operating cash flow of -$16.69M in Q1 2026.
How has Trevi Therapeutics, Inc.'s operating cash flow changed year-over-year?
Trevi Therapeutics, Inc.'s operating cash flow decreased by 23.8% year-over-year, from -$13.48M to -$16.69M.
What is the long-term trend for Trevi Therapeutics, Inc.'s operating cash flow?
Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s operating cash flow has grown at a 9.8% compound annual growth rate (CAGR), from -$28.95M to -$42.09M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Trevi Therapeutics, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude